Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Citizens BancShares Inc (FCNCA) vs Johnson & Johnson (JNJ) Price & Performance

First Citizens BancShares IncTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

First Citizens BancShares Inc vs Johnson & Johnson — how do they compare? First Citizens BancShares Inc trades at $2,252.54 (market cap $25.04B), while Johnson & Johnson trades at $260.44 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 25× First Citizens BancShares Inc's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.

FCNCAJNJ
Market Cap
$25.04B$626.09B
Sector
Sector/ThematicHealth
52-Week High
$2.25K$267.24
52-Week Low
$1.64K$172.78
Dividend Yield
0.37%2.06%
Volume
6,156,228
Enterprise Value
$654.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Citizens BancShares Inc

First Citizens BancShares (FCNCA) trades at $2,258.55, up 1.13% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by positive cash flow trends and strategic expansions in commercial banking services. Recent news highlights institutional investments and new leadership appointments, reinforcing growth initiatives.

Outlook remains favorable due to consistent earnings outperformance and expanding business segments, though risks include elevated uninsured deposits and net interest margin pressure. Analyst consensus is mixed with a hold-heavy rating, but the stock offers value with upside to the $2,310 price target. Investors should weigh solid profitability against sector-specific headwinds.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.

The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Citizens BancShares Inc

First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.

Read more on FCNCA

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ